TARA Stock Risk & Deep Value Analysis

Protara Therapeutics Inc

Healthcare • Biotechnology

DVR Score

4.8

out of 10

Proceed with Caution

The Bottom Line on TARA

We analyzed Protara Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran TARA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Mar 12, 2026•Run Fresh Analysis →

📈TARA Performance Overview3yr weekly

📊

Unlock TARA Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

TARA Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

High

Market Risk

Low

About Protara Therapeutics Inc (TARA)

Sector

Healthcare

Industry

Biotechnology

Market Cap Category

small

Market Cap

$243.10M

TARA Deep Value Analysis

Protara Therapeutics (TARA) continues to represent a high-risk, high-reward investment opportunity, mirroring our assessment from 22 days ago. The investment thesis remains predominantly tied to the binary outcome of its lead asset, TARA-002, in the global Phase 3 trial for refractory lymphatic malformations (LM), with results still anticipated in late 2026 / early 2027. This orphan indication, coupled with Fast Track designation, signifies a substantial unmet medical need and potential for market leadership, justifying the projected 10x upside upon clinical success. However, critical concerns regarding the company's precarious financial health, characterized by a high cash burn rate, persist. This necessitates future financing rounds and carries a material risk of significant dilution, severely impacting the probability of realizing the full upside. Given no material operational or financial news has emerged since the last analysis, the overall investment thesis remains unchanged, balancing speculative long-term growth against immediate clinical and financial challenges. The current score reflects the significant potential offset by substantial inherent risks.

TARA Red Flags & Warning Signs

Premium

⚠
Negative or inconclusive Phase 3 trial results for TARA-002.
⚠
Inability to secure sufficient future funding, leading to significant dilution or operational slowdown.
⚠
Adverse safety signals from ongoing trials.
⚠
Competitor developing an alternative therapy for LM.

Unlock TARA Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

TARA Financial Health Metrics

Market Cap

$243.10M

TARA Competitive Moat Analysis

Premium

Moat Rating

Narrow

Moat Trend

Expanding

Moat Sources

2 Identified

Intangible Assets/IP (patents for TARA-002)Regulatory Advantages (Orphan Drug, Fast Track)

The moat is currently nascent but has the potential to become narrow and durable if TARA-002 successfully completes Phase 3 trials and receives regulatory approval. Patent protection, market exclusivity from orphan drug status, and the inherent difficulty for competitors to replicate a successful clinical trial outcome would provide a strong, albeit time-limited, competitive advantage.

TARA Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

TARA Catalysts & Growth Drivers

Near-Term (0-6 months)

•Q4 2025 Earnings Call (Estimated Early May 2026): Focus on cash runway and R&D updates.
•Clinical trial updates on TARA-002 enrollment progress (Any ad-hoc announcements).

Medium-Term (6-18 months)

•Anticipation of top-line Phase 3 trial results for TARA-002 in LM (Late 2026 / Early 2027).

Long-Term (18+ months)

•Potential regulatory submission and approval of TARA-002 for LM (2027-2028).
•Commercialization and market penetration of TARA-002 (2028+).
•Pipeline expansion or new indication development.

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

TARA Bull Case: What Could Go Right

✓
Successful and timely completion of TARA-002 Phase 3 trial enrollment.
✓
Any positive interim data or early readouts from the TARA-002 trial.
✓
New financing rounds that demonstrate manageable dilution and extend cash runway beyond 12-18 months.
✓
Updates on regulatory interactions and potential for accelerated approval pathways.

Bull Case Analysis

See what could go right with Premium

🔔

Never miss a move on TARA

Create a free account to set price alerts and get notified on Telegram when TARA hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Protara Therapeutics Inc (TARA)?

As of March 12, 2026, Protara Therapeutics Inc has a DVR Score of 4.8 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Protara Therapeutics Inc?

Protara Therapeutics Inc's market capitalization is approximately $243.1M. The company operates in the Healthcare sector within the Biotechnology industry.

What ticker symbol does Protara Therapeutics Inc use?

TARA is the ticker symbol for Protara Therapeutics Inc. The company trades on the NGM.

What is the risk level for TARA stock?

Our analysis rates Protara Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the TARA DVR analysis updated?

Our AI-powered analysis of Protara Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 12, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.